Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Defining Clinical Utility of Germline Indicators of Toxicity Risk: A Perspective
Daniel L. Hertz, Lisa M. McShane, Daniel F. Hayes
Journal of Clinical Oncology (2022) Vol. 40, Iss. 16, pp. 1721-1731
Open Access | Times Cited: 11

Showing 11 citing articles:

Response to the FDA Decision Regarding DPYD Testing Prior to Fluoropyrimidine Chemotherapy
Daniel L. Hertz, D. Max Smith, Stuart A. Scott, et al.
Clinical Pharmacology & Therapeutics (2023) Vol. 114, Iss. 4, pp. 768-779
Open Access | Times Cited: 23
Systemic inflammation and cancer-related frailty: shifting the paradigm toward precision survivorship medicine
Antonio Di Meglio, Inês Vaz-Luís
ESMO Open (2024) Vol. 9, Iss. 1, pp. 102205-102205
Open Access | Times Cited: 7
Assessment of the Clinical Utility of PretreatmentDPYDTesting for Patients Receiving Fluoropyrimidine Chemotherapy
Daniel L. Hertz
Journal of Clinical Oncology (2022) Vol. 40, Iss. 33, pp. 3882-3892
Closed Access | Times Cited: 20
Cost-utility analysis and cross-country comparison of pharmacogenomics-guided treatment in colorectal cancer patients participating in the U-PGx PREPARE study
Vasileios Fragoulakis, Rossana Roncato, Alessia Bignucolo, et al.
Pharmacological Research (2023) Vol. 197, pp. 106949-106949
Open Access | Times Cited: 12
Checkpoint inhibitors and anti-angiogenic agents: a winning combination
Patrick Brest, Baharia Mograbi, Gilles Pagès, et al.
British Journal of Cancer (2023) Vol. 129, Iss. 9, pp. 1367-1372
Open Access | Times Cited: 10
Attempted replication of pharmacogenetic association of variants in PPP1R14C and CCDC148 with aromatase inhibitor-induced musculoskeletal symptoms
Yuqing Liang, Christina L. Gersch, Jennifer Lehman, et al.
Pharmacogenetics and Genomics (2024)
Closed Access | Times Cited: 1
Potential association of SULT2A1 and ABCG2 variant alleles with increased risk for palbociclib toxicity
Chong Wang, Mary Hwang, Brandon Paulson, et al.
Pharmacogenomics (2024) Vol. 25, Iss. 8-9, pp. 367-375
Closed Access | Times Cited: 1
Abigene, a Prospective, Multicentric Study of Abiraterone Acetate Pharmacogenetics in Metastatic Castration-Resistant Prostate Cancer
Jean-­Marc Ferrero, Hakim Mahammedi, Gwénaëlle Gravis, et al.
Pharmaceutics (2023) Vol. 15, Iss. 2, pp. 651-651
Open Access | Times Cited: 3
Integrating pharmacogenomic testing into paired germline and somatic genomic testing in patients with cancer
Nathan D. Seligson, Jill Kolesar, Benish Alam, et al.
Pharmacogenomics (2023) Vol. 24, Iss. 13, pp. 731-738
Closed Access | Times Cited: 3
Using real world data to advance the provision of supportive cancer care: mucositis as a case study
Hannah R. Wardill, Steve T. Sonis, Nicole M. A. Blijlevens
Current Opinion in Supportive and Palliative Care (2022) Vol. 16, Iss. 3, pp. 161-167
Closed Access | Times Cited: 3
Taxane-Induced Peripheral Neuropathy among Early-Stage Breast Cancer Survivors : Prevalence, Risk Factors, Quality of Life and Genetic Prediction Models
K. Engvall
Linköping University medical dissertations (2024)
Open Access
Page 1

Scroll to top